Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

Panelists discuss how chronic spontaneous urticaria involves autoantibody-mediated mast cell activation and degranulation, with BTK serving as a critical signaling molecule in both mast cells and B cells that produce pathogenic autoantibodies.

Now Viewing

EP: 1.Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP: 2.Pathophysiology of Chronic Spontaneous Urticaria

EP: 3.Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

EP: 4.BTK Inhibition as a Strategy for CSU Treatment

EP: 5.How BTK Inhibitors Differ From Current CSU Treatment Approaches

Video content above is prompted by the following:

Please provide a brief overview of the pathophysiology of chronic spontaneous urticaria (CSU), including the role of Bruton Tyrosine Kinase (BTK).
How would targeting BTK through inhibition be a strategy in the treatment of CSU?
Briefly preview the two BTK inhibitors currently in development for CSU (remibrutinib and rilzabrutinib), including what phase of development each is in and what kind of data is currently published or expected.